HOLDEN, Mass.--(BUSINESS WIRE)--Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University. “These compounds were designed to be degraded rapidly by enzymes at or near the site of application after the therapeutic effect is achieved so that there are no systemic effects on other organs and that’s exactly what they do in our new studies,” stated Dr. Yael Schwartz, CEO. Currently marketed FDA-approved treatments for VVA carry strong Black Box warnings of increased risk of breast and endometrial cancers as well as stroke. Because of the risk profile for currently marketed topical estrogens, the FDA mandates that estrogens be used for the shortest time possible and at the lowest effective dose.
